This opportunity uses the R01 Research Project Grant funding mechanism.
This supports the development and evaluation of novel targeting technologies to deliver anti-HIV gene therapies to specific cells or sites in vivo. Some of the challenges to be overcome with in vivo gene therapeutic strategies are:
- inefficient delivery to specific target cells and sites;
- selective regulation of genetic payload expression to maximise on-target efficacy and minimise off-target effects;
- the potential immunogenicity of delivery vectors and transgenes themselves.
Funding & Duration
Application budgets are not limited but need to reflect the actual needs of the proposed project.
The maximum project period is five years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Dates
- 30 June 2018 – Letter of Intent (LOI) via Grants.Gov submission portal.
- 17 July 2018 – full applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review